Horizon 1 1 17 ACLN : Articles dans des revues avec comité de lecture non répertoriées par l'AERES Comparative Biochemistry and Physiology 51-54 LEISHMANIOSE TRAITEMENT MEDICAL EFFICACITE ETUDE EXPERIMENTALE PLANTE MEDICINALE EXTRACTION ANIMAL DE LABORATOIRE LICHEN ACIDE USNIQUE PANNARINE CHLOROPANNARINE 1997 fdi:010009663 ENG Comparative Biochemistry and Physiology 0742-8413 1 https://www.documentation.ird.fr/hor/fdi:010009663 https://horizon.documentation.ird.fr/exl-doc/pleins_textes/pleins_textes_6/b_fdi_45-46/010009663.pdf 116C Horizon (IRD) Three secondary metabolites isolated from Chilean lichens, (+) usnic acid, pannarine and 1'-chloropannarine, were tested against promastigotes forms of three strains of #Leishmania$ ssp. Pannarine and 1'-chloropannarine exhibited in vitro activity at 50 microg/ml and (+) usnic acid at 25 microg/ml. BALB/c mice infected with #Leishmania amazonensis$ were treated 4 weeks post-infection with (+) usnic acid by subcutaneous or oral routes for 15 days at 25 mg/kg or by five intralesional injections at interval of 4 days at 25 mg/kg of body weight. The reference drug, N-methylglucamine antimonate (Glucantime), was administered by subcutaneous injections (regimens of 28 mg of pentavalent antimony) for 15 days. The subcutaneous and oral treatments with (+) usnic did not produce any effect, but by intralesional administration we observed a significant effect that reduced by 43.34% the weight lesions and by 72.28% the parasites loads in infected footpads. (Résumé d'auteur) 052PHLEIS03 ; 076PLAMED03